Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 7/20 | 0.47 |
| ▸ | ITK | Q08881 | 7/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | MAP3K12 | Q12852 | 7/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20132603 | 0.83 | MET (0.44) | METBTKITKCCNT1CCNA2 | |
| SCHEMBL19937778 | 0.77 | BTK (0.47) | METBTKITKAXLMAP3K12 | |
| SCHEMBL13560244 | 0.73 | KIT (0.59) | BTKITKCCNT1CCNA2CDK2 | |
| SCHEMBL7921128 | 0.73 | MET (0.46) | METBTKITKAXLMAP3K12 | |
| SCHEMBL27842922 | 0.72 | CCR1 (0.61) | CCR1CCR5CCR8CYP2A6 | |
| SCHEMBL15344950 | 0.72 | BRD4 (0.49) | CCNT1CCNA2CDK2CDK9CCR1 | |
| SCHEMBL9967201 | 0.71 | CCNT1 (0.47) | CCNT1CCNA2CDK2CDK9CCR1 | |
| SCHEMBL15345021 | 0.71 | CCR1 (0.46) | CCR1CCR5CCR8CYP2A6 | |
| SCHEMBL18471246 | 0.70 | CCR1 (0.64) | CCR1CCR5CCR8CYP2A6 | |
| SCHEMBL19937589 | 0.70 | MAP3K12 (0.56) | METMAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885BTK 1148/4885ITK 3422/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | MET 3530/4885BTK 1148/4885ITK 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.